Global Artificial Pancreas Devices System Market 2016-2020

  • ID: 4013319
  • Report
  • Region: Global
  • 85 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Beta Bionics
  • Cellnovo
  • Dose Safety
  • Inreda Diabetic
  • Johnson & Johnson
  • Roche
  • MORE
About Artificial Pancreas Devices System

Artificial organs are human-made bioartificial devices, which are implanted or integrated into individuals to replace or support natural organs. These include artificial heart, kidney, pancreas, and cochlear implants. Biocompatible materials such as polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ceramics, and metals are used to develop artificial organs. These organs are incorporated with different technologies like sensors, biomaterials, and innovative delivery systems. Artificial organs perform the function of the natural organ and help the patient to live a quality life. In few cases, artificial organs are capable of eliminating the need for organ transplantation altogether.

Analysts forecast the global artificial pancreas devices system market to grow at a CAGR of 7.40% during the period 2016-2020.

Covered in This Report:
The report covers the present scenario and the growth prospects of the global artificial pancreas devices system market for 2016-2020. To calculate the market size, the report considers the revenue generated from sales of the different products.

The Market is Divided into the Following Segments Based on Geography:
- Americas
- APAC
- EMEA

Global Artificial Pancreas Devices System Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors:
- Medtronic
- Johnson & Johnson
- Insulet
- Tandem Diabetes Care
- Roche

Other Prominent Vendors:
- Beta Bionics
- Bigfoot Biomedical
- Cellnovo
- Dexcom
- Dose Safety
- DreaMed Diabetes
- Inreda Diabetic
- Type Zero Technologies

Market Drivers:
- Growing technological integration fueling the market growth.
- For a full, detailed list, view the full report

Market challenges:
- Lack of smart control algorithms affecting the adoption rate of existing APDS.
- For a full, detailed list, view the full report

Market Trends:
- Growing demand for remote monitoring application.
- For a full, detailed list, view the full report

Key Questions Answered in This Report:
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Beta Bionics
  • Cellnovo
  • Dose Safety
  • Inreda Diabetic
  • Johnson & Johnson
  • Roche
  • MORE
Part 01: Executive summary
  • Highlights
Part 02: Scope of the report
  • Market overview
  • Assumptions
  • Top-vendor offerings
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
  • A glance at parent market: Artificial organs
Part 05: An overview of pancreas and diabetes
  • Pancreas
  • Diabetes
  • Insulin overview
Part 06: Need for better systems in the management of diabetes

Part 07: Artificial pancreas device system
  • Technology landscape
Part 08: Initiatives for the development of APDS
  • Juvenile Diabetes Research Foundation (JDRF) initiative — 2006
  • European Commission’s AP@home project — 2010
  • Centre for bio-inspired technology — Bionic pancreas
  • Harvard University — 2014
Part 09: FDA’s role in fostering the development of APDS
  • Rapid response to preliminary study plans
  • Interactive review of investigational device exemption study plans
  • Guidance and standards for researchers and industry
Part 10: Reimbursement scenario
  • Australia
  • Germany
  • UK
  • US
Part 11: Key clinical trials

Part 12: Market landscape
  • Market overview
  • Five forces analysis
Part 13: Market segmentation by categories
  • TSDS
  • NTSDS
  • CTRS
  • CTTS
Part 14: Geographical segmentation
  • APDS market in Americas
  • APDS market in EMEA
  • APDS market in APAC
Part 15: Market drivers
  • Growing technological integration fuelling the market growth
  • Increasing initiatives of research organizations fostering innovation in the market
  • Increasing prevalence of diabetes fuelling the need for effective devices
Part 16: Impact of drivers

Part 17: Market challenges
  • Lack of smart control algorithms affecting the adoption rate of existing APDS
  • Low penetration rates affecting the market growth
  • Lab-grown pancreatic cell transplant as a potential treatment alternative hindering the growth prospects
Part 18: Impact of drivers and challenges

Part 19: Market trends
  • Increasing focus on closed loop systems
  • Growing demand for remote monitoring applications
  • Focus of new entrants on the development of novel APDS
Part 20: Vendor landscape
  • Competitive scenario
Part 21: Key vendor analysis
  • Medtronic
  • Johnson & Johnson
  • Insulet
  • Tandem Diabetes Care
  • Roche
  • Other prominent vendors
Part 22: Appendix
  • List of abbreviations
Part 23: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key segments in artificial organ market
Exhibit 03: Diagnosis of diabetes by blood sugar test
Exhibit 04: Diagnosis of diabetes by glycated hemoglobin test
Exhibit 05: Treatment algorithm for type 2 diabetes
Exhibit 06: Factors that fuelled the need for APDS
Exhibit 07: Technology involved in the functioning of APDS
Exhibit 08: Barriers in CGM
Exhibit 09: Barriers in hormonal pumps
Exhibit 10: Key findings of researchers related to algorithms till date
Exhibit 11: Key clinical trials
Exhibit 12: Global APDS market snapshot
Exhibit 13: Development path of APDS
Exhibit 14: Global APDS market 2015-2020 ($ millions)
Exhibit 15: Key factors driving the demand for closed loop systems
Exhibit 16: Scenario analysis of global APDS market
Exhibit 17: Five forces analysis
Exhibit 18: Pipeline products
Exhibit 19: Key pipeline products
Exhibit 20: Scenario analysis of key segments in global APDS market
Exhibit 21: Segmentation of global APDS market based on geography 2015 and 2020
Exhibit 22: APDS market revenue by geography 2015-2020 ($ millions)
Exhibit 23: Market scenario in Americas
Exhibit 24: APDS market in the Americas ($ millions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: APDS market in EMEA ($ millions)
Exhibit 27: Market scenario in EMEA
Exhibit 28: APDS market in APAC ($ millions)
Exhibit 29: Key technological integrations
Exhibit 30: Key initiatives of research organizations
Exhibit 31: Incidence and prevalence for diabetes in the US
Exhibit 32: Traditional systems vs APDS
Exhibit 33: Impact of drivers
Exhibit 34: Forcefield analysis of drivers and challenges
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Key trends in the development of closed loop systems
Exhibit 37: Key products under development for remote monitoring applications
Exhibit 38: New entrants and their expected product launches
Exhibit 39: Competitive structure analysis of global APDS market 2015
Exhibit 40: Competitive analysis of global APDS market
Exhibit 41: Market share analysis 2015
Exhibit 42: Market penetration of various APDS manufacturers in global (2015)
Exhibit 43: Timeline chart representing the development of APDS
Exhibit 44: Strategic success factors of companies in global APDS market
Exhibit 45: Key highlights
Exhibit 46: Strength assessment
Exhibit 47: Strategy assessment
Exhibit 48: Opportunity assessment
Exhibit 49: Key highlights
Exhibit 50: Strength assessment
Exhibit 51: Strategy assessment
Exhibit 52: Opportunity assessment
Exhibit 53: Key highlights
Exhibit 54: Strength assessment
Exhibit 55: Strategy assessment
Exhibit 56: Opportunity assessment
Exhibit 57: Key highlights
Exhibit 58: Strength assessment
Exhibit 59: Strategy assessment
Exhibit 60: Opportunity assessment
Exhibit 61: Key highlights
Exhibit 62: Strength assessment
Exhibit 63: Strategy assessment
Exhibit 64: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Beta Bionics
  • Cellnovo
  • Dose Safety
  • Inreda Diabetic
  • Johnson & Johnson
  • Roche
  • MORE
Global Artificial Pancreas Devices System Market 2016-2020

Key players in the global artificial pancreas devices system market: Medtronic, Johnson & Johnson, Insulet, Tandem Diabetes Care, and Roche.

Other Prominent Vendors in the market are: Beta Bionics, Bigfoot Biomedical, Cellnovo, Dexcom, Dose Safety, DreaMed Diabetes, Inreda Diabetic, and Type Zero Technologies.

Commenting on the report, an analyst from the team said: “One trend in the market is increasing focus on closed loop systems. The increasing demand for APDS has driven the vendors to undertake extensive clinical trials toward product improvement, which are expected to have a positive impact on the market growth. The vendors such as Medtronic, Tandem Diabetes Care, Johnson & Johnson, and Insulet are currently focusing on the development of closed loop APDS, which is expected to propel the market growth owing to its potential advantages compared with existing APDS. The existing open loop APDS are low glucose suspend devices with semi-automation. As these systems are not integrated with advanced algorithms, the required user intervention is at a moderate level. On the contrary, closed-loop APDS are externally worn medical devices, which would enable individuals with type 1 diabetes to regulate blood glucose levels in a fully automated way with zero intervention required from the user.”

According to the report, one driver in the market is increasing initiatives of research organizations fostering innovation in the market. The inspiring initiatives of research organizations such as JDRF enable the development of innovative products in the market. JDRF launched Artificial Pancreas Project in 2006 to foster the development of an artificial pancreas to help individuals with diabetes. Subsequently, JDRF collaborated with Medtronic in 2014 to develop a novel redundant sensor system, which is designed to boost the accuracy and reliability of APDS. The research also focused on the development of orthogonally redundant sensor system, which integrates an electrochemical sensor along with an optical sensor to provide accurate glucose values. Earlier, in June 2013, JDRF collaborated with BD for a three-year time period to develop a single optimized device that will handle multiple functions and avoid the need and complexities of dwelling catheters. Recently, the researchers at Harvard University started a program to identify and develop an effective treatment for type 1 diabetes. Subsequently, National Institutes of Health awarded $12.5 million to Harvard University in 2016 to undertake the field testing of two artificial pancreas algorithms. Such initiatives lead to the development of novel products as well as upgradation of existing systems.

Further, the report states that one challenge in the market is lack of smart control algorithms affecting the adoption rate of existing APDS. Though there are important developments in sensor and pump technology, the APDS is associated with the delays and inaccuracies in glucose sensing and insulin delivery. Such type of issues occurs when there is a disturbance in the routine system (such as uptake of meal), which triggers a rapid glucose rise that is significantly faster than the time required for insulin absorption and action. Thus, the vendors should focus on designing an APDS with smart sensors that consider a relatively slow response, giving time for the delays to fade before the next control action. In particular, to avoid hypoglycemia after a meal, the vendors has to design a moderately aggressive controller. This has driven the vendors to research on new control design, model predictive control (MPC) algorithm, which is based on a prediction of glucose dynamics using a model of the individual's metabolic system. According to clinical studies, this design may be better for mitigation of time delays due to subcutaneous glucose sensing and insulin infusion. However, such smart algorithms have limited clinical evidence, and it may take few more years to develop an ideal algorithm.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Medtronic
  • Johnson & Johnson
  • Insulet
  • Tandem Diabetes Care
  • Roche
  • Beta Bionics
  • Bigfoot Biomedical
  • Cellnovo
  • Dexcom
  • Dose Safety
  • DreaMed Diabetes
  • Inreda Diabetic
  • Type Zero Technologies.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll